BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 33423239)

  • 1. Dipeptidyl peptidase-4 inhibitors may accelerate cirrhosis decompensation in patients with diabetes and liver cirrhosis: a nationwide population-based cohort study in Taiwan.
    Yen FS; Wei JC; Yip HT; Hwu CM; Hou MC; Hsu CC
    Hepatol Int; 2021 Feb; 15(1):179-190. PubMed ID: 33423239
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Thiazolidinediones were associated with higher risk of cardiovascular events in patients with type 2 diabetes and cirrhosis.
    Yen FS; Wei JC; Chiu LT; Hsu CC; Hou MC; Hwu CM
    Liver Int; 2021 Jan; 41(1):110-122. PubMed ID: 33124143
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metformin use and cirrhotic decompensation in patients with type 2 diabetes and liver cirrhosis.
    Yen FS; Huang YH; Hou MC; Hwu CM; Lo YR; Shin SJ; Hsu CC
    Br J Clin Pharmacol; 2022 Jan; 88(1):311-322. PubMed ID: 34198358
    [TBL] [Abstract][Full Text] [Related]  

  • 4. All-cause mortality of insulin plus dipeptidyl peptidase-4 inhibitors in persons with type 2 diabetes.
    Yen FS; Chiang JH; Hwu CM; Yen YH; Lin BJ; Wei JC; Hsu CC
    BMC Endocr Disord; 2019 Jan; 19(1):3. PubMed ID: 30611254
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Is insulin the preferred treatment in persons with type 2 diabetes and liver cirrhosis?
    Yen FS; Lai JN; Wei JC; Chiu LT; Hsu CC; Hou MC; Hwu CM
    BMC Gastroenterol; 2021 Jun; 21(1):263. PubMed ID: 34118892
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glucagon-Like Peptide-1 Receptor Agonists and Hepatic Decompensation Events in Patients With Cirrhosis and Diabetes.
    Simon TG; Patorno E; Schneeweiss S
    Clin Gastroenterol Hepatol; 2022 Jun; 20(6):1382-1393.e19. PubMed ID: 34256144
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glucagon-like Peptide-1 Receptor Agonist Use in Patients With Liver Cirrhosis and Type 2 Diabetes.
    Yen FS; Hou MC; Cheng-Chung Wei J; Shih YH; Hsu CY; Hsu CC; Hwu CM
    Clin Gastroenterol Hepatol; 2024 Jun; 22(6):1255-1264.e18. PubMed ID: 37331413
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dipeptidyl Peptidase-4 Inhibitors and Risk of Heart Failure in Patients With Type 2 Diabetes Mellitus: A Population-Based Cohort Study.
    Kim YG; Yoon D; Park S; Han SJ; Kim DJ; Lee KW; Park RW; Kim HJ
    Circ Heart Fail; 2017 Sep; 10(9):. PubMed ID: 28899989
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The associations of sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors as add-on to metformin with fracture risk in patients with type 2 diabetes mellitus.
    van Hulten V; Driessen JHM; Starup-Linde JK; Al-Mashhadi ZK; Viggers R; Klungel OH; Souverein PC; Vestergaard P; Stehouwer CDA; van den Bergh JP
    Diabetes Obes Metab; 2023 Nov; 25(11):3235-3247. PubMed ID: 37503747
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cardiovascular Outcomes of Dipeptidyl Peptidase-4 Inhibitors in Elderly Patients With Type 2 Diabetes: A Nationwide Study.
    Shih CJ; Chen HT; Kuo SC; Ou SM; Chen YT
    J Am Med Dir Assoc; 2016 Jan; 17(1):59-64. PubMed ID: 26612484
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dipeptidyl peptidase-4 inhibitors and the risks of autoimmune diseases in type 2 diabetes mellitus patients in Taiwan: a nationwide population-based cohort study.
    Chen YC; Chen TH; Sun CC; Chen JY; Chang SS; Yeung L; Tsai YW
    Acta Diabetol; 2020 Oct; 57(10):1181-1192. PubMed ID: 32318876
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects on Clinical Outcomes of Adding Dipeptidyl Peptidase-4 Inhibitors Versus Sulfonylureas to Metformin Therapy in Patients With Type 2 Diabetes Mellitus.
    Ou SM; Shih CJ; Chao PW; Chu H; Kuo SC; Lee YJ; Wang SJ; Yang CY; Lin CC; Chen TJ; Tarng DC; Li SY; Chen YT
    Ann Intern Med; 2015 Nov; 163(9):663-72. PubMed ID: 26457538
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dipeptidyl peptidase-4 inhibitors attenuates osteoporosis in patients with diabetes: A nationwide, retrospective, matched-cohort study in Taiwan.
    Chang CH; Lu CH; Chung CH; Su SC; Kuo FC; Liu JS; Li PF; Huang CL; Chen KC; Ho LJ; Kuo CC; Chang CY; Lin MS; Liu YC; Chu NF; Lee CH; Hung YJ; Hsieh PS; Lin FH; Hsieh CH; Chien WC
    J Chin Med Assoc; 2022 Jul; 85(7):747-753. PubMed ID: 35648138
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risks of cardiovascular diseases associated with dipeptidyl peptidase-4 inhibitors and other antidiabetic drugs in patients with type 2 diabetes: a nation-wide longitudinal study.
    Ou HT; Chang KC; Li CY; Wu JS
    Cardiovasc Diabetol; 2016 Mar; 15():41. PubMed ID: 26932742
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cardiovascular risks associated with dipeptidyl peptidase-4 inhibitors monotherapy compared with other antidiabetes drugs in the Japanese population: A nationwide cohort study.
    Komamine M; Kajiyama K; Ishiguro C; Uyama Y
    Pharmacoepidemiol Drug Saf; 2019 Sep; 28(9):1166-1174. PubMed ID: 31338935
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association between Dipeptidyl Peptidase-4 Inhibitors and Allergic Rhinitis in Asian Patients with Diabetes.
    Chen HH; Li SY; Chen W; Kao CH
    Int J Environ Res Public Health; 2019 Apr; 16(8):. PubMed ID: 31013793
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cardiovascular safety of evogliptin in patients with type 2 diabetes: A nationwide cohort study.
    Park SH; Jeong HE; Oh IS; Hong SM; Yu SH; Lee CB; Shin JY
    Diabetes Obes Metab; 2021 Jun; 23(6):1232-1241. PubMed ID: 33502058
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dipeptidyl peptidase-4 inhibitors and cardiovascular risks in patients with pre-existing heart failure.
    Ou SM; Chen HT; Kuo SC; Chen TJ; Shih CJ; Chen YT
    Heart; 2017 Mar; 103(6):414-420. PubMed ID: 27647170
    [TBL] [Abstract][Full Text] [Related]  

  • 19. No increased risk of cardiovascular events in older adults initiating dipeptidyl peptidase-4 inhibitors vs therapeutic alternatives.
    Gokhale M; Buse JB; Jonsson Funk M; Lund J; Pate V; Simpson RJ; Stürmer T
    Diabetes Obes Metab; 2017 Jul; 19(7):970-978. PubMed ID: 28195389
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness and safety of sodium-glucose co-transporter-2 inhibitors compared with dipeptidyl peptidase-4 inhibitors in older adults with type 2 diabetes: A nationwide population-based study.
    Han SJ; Ha KH; Lee N; Kim DJ
    Diabetes Obes Metab; 2021 Mar; 23(3):682-691. PubMed ID: 33236515
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.